Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.48 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.47 |
| ▸ | FES | P07332 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18580753 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP3A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4246691 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2CYP3A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL18612365 | 0.83 | AURKB (0.48) | SMN1; SMN2CYP3A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL18580399 | 0.82 | CSNK1D (0.53) | SMN1; SMN2KCNH2EPHX2ALDH1A1DYRK1A | |
| SCHEMBL28623538 | 0.82 | CYP1A2 (0.73) | SMN1; SMN2CYP3A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL18580663 | 0.81 | DYRK1A (0.44) | SMN1; SMN2CYP3A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL18580843 | 0.81 | POLB (0.49) | SMN1; SMN2CYP3A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL18579782 | 0.81 | DCLK1 (0.44) | SMN1; SMN2CYP3A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10963928 | 0.81 | MAPT (0.54) | SMN1; SMN2CYP3A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL21471354 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP3A4CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11083717-B2 | Compositions and methods for drug sensitization of parasites | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2021-08-10 | — | — | US | disclosed |
| US-11083717-B2 | Compositions and methods for drug sensitization of parasites | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3659597-A2 | COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES | The Texas A&M University System (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20200138796-A1 | COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES | THE TEXAS A&M UNIVERSITY SYSTEM | 2020-05-07 | — | — | US | disclosed |
| US-20200138796-A1 | COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES | THE TEXAS A&M UNIVERSITY SYSTEM | 2020-05-07 | — | — | US | disclosed |
| US-10543200-B2 | Compositions and methods for drug sensitization of parasites | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2020-01-28 | — | — | US | disclosed |
| US-10543200-B2 | Compositions and methods for drug sensitization of parasites | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190314381-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA | THE TEXAS A&M UNIVERSITY SYSTEM | 2019-10-17 | — | — | US | disclosed |
| US-20190314381-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA | THE TEXAS A&M UNIVERSITY SYSTEM | 2019-10-17 | — | — | US | disclosed |
| US-10300071-B2 | Compositions and methods for inhibition of mycobacteria | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2019-05-28 | — | — | US | disclosed |
| US-10300071-B2 | Compositions and methods for inhibition of mycobacteria | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180243275-A1 | COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES | THE TEXAS A&M UNIVERSITY SYSTEM | 2018-08-30 | — | — | US | disclosed |
| US-20170065601-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA | THE TEXAS A&M UNIVERSITY SYSTEM | 2017-03-09 | — | — | US | disclosed |
| US-20170065601-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA | THE TEXAS A&M UNIVERSITY SYSTEM | 2017-03-09 | — | — | US | disclosed |
| US-20170065601-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA | THE TEXAS A&M UNIVERSITY SYSTEM | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300071-B2 | Compositions and methods for inhibition of mycobacteria | ME3, PGLS, GNPAT | SMN1; SMN2 4812/4885CYP3A4 387/4885CYP1A2 706/4885 |
| US-20180243275-A1 | COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES | ABCC1, SLC11A2, CYP3A43 | SMN1; SMN2 4303/4885CYP3A4 60/4885CYP1A2 54/4885 |
| US-20190314381-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA | ME3, PGLS, GNPAT | SMN1; SMN2 4812/4885CYP3A4 387/4885CYP1A2 706/4885 |
| US-20200138796-A1 | COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES | ABCC1, SLC11A2, ABCG2 | SMN1; SMN2 4367/4885CYP3A4 75/4885CYP1A2 90/4885 |
| US-10543200-B2 | Compositions and methods for drug sensitization of parasites | ABCC1, SLC11A2, ABCG2 | SMN1; SMN2 4367/4885CYP3A4 75/4885CYP1A2 90/4885 |
| US-11083717-B2 | Compositions and methods for drug sensitization of parasites | ABCC1, SLC11A2, ABCG2 | SMN1; SMN2 4367/4885CYP3A4 75/4885CYP1A2 90/4885 |
| US-20170065601-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA | ME3, PGLS, GNPAT | SMN1; SMN2 4812/4885CYP3A4 387/4885CYP1A2 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.